Umeå University's logo

umu.sePublications
Change search
Link to record
Permanent link

Direct link
Larsson, Anne
Alternative names
Publications (10 of 74) Show all publications
Koole, M., Amstrong, I., Krizsan, A. K., Strömvall, A., Visvikis, D., Sattler, B., . . . Dickson, J. (2023). EANM guidelines for PET-CT and PET-MR routine quality control. Zeitschrift für Medizinische Physik, 33(1), 103-113
Open this publication in new window or tab >>EANM guidelines for PET-CT and PET-MR routine quality control
Show others...
2023 (English)In: Zeitschrift für Medizinische Physik, ISSN 0939-3889, E-ISSN 1876-4436, Vol. 33, no 1, p. 103-113Article in journal (Refereed) Published
Abstract [en]

We present guidelines by the European Association of Nuclear Medicine (EANM) for routine quality control (QC) of PET-CT and PET-MR systems. These guidelines are partially based on the current EANM guidelines for routine quality control of Nuclear Medicine instrumentation but focus more on the inherent multimodal aspect of the current, state-of-the-art PET-CT and PET-MR scanners. We briefly discuss the regulatory context put forward by the International Electrotechnical Commission (IEC) and European Commission (EC) and consider relevant guidelines and recommendations by other societies and professional organizations. As such, a comprehensive overview of recommended quality control procedures is provided to ensure the optimal operational status of a PET system, integrated with either a CT or MR system. In doing so, we also discuss the rationale of the different tests, advice on the frequency of each test and present the relevant MR and CT tests for an integrated system. In addition, we recommend a scheme of preventive actions to avoid QC tests from drifting out of the predefined range of acceptable performance values such that an optimal performance of the PET system is maintained for routine clinical use.

Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
Guidelines, PET-CT, PET-MR, Quality control
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-200076 (URN)10.1016/j.zemedi.2022.08.003 (DOI)36167600 (PubMedID)2-s2.0-85138826478 (Scopus ID)
Available from: 2022-10-10 Created: 2022-10-10 Last updated: 2023-05-02Bibliographically approved
af Bjerkén, S., Axelsson, J., Larsson, A., Flygare, C., Remes, J., Strandberg, S., . . . Jakobson Mo, S. (2023). Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease. Nuclear medicine communications, 44(5), 397-406
Open this publication in new window or tab >>Reliability and validity of visual analysis of [18F]FE-PE2I PET/CT in early Parkinsonian disease
Show others...
2023 (English)In: Nuclear medicine communications, ISSN 0143-3636, E-ISSN 1473-5628, Vol. 44, no 5, p. 397-406Article in journal (Refereed) Published
Abstract [en]

Objective: [18F]FE-PE2I (FE-PE2I) is a new radiotracer for dopamine transporter (DAT) imaging with PET. The aim of this study was to evaluate the visual interpretation of FE-PE2I images for the diagnosis of idiopathic Parkinsonian syndrome (IPS). The inter-rater variability, sensitivity, specificity, and diagnostic accuracy for visual interpretation of striatal FE-PE2I compared to [123I]FP-CIT (FP-CIT) single-photon emission computed tomography (SPECT) was evaluated.

Methods: Thirty patients with newly onset parkinsonism and 32 healthy controls with both an FE-PE2I and FP-CIT were included in the study. Four patients had normal DAT imaging, of which three did not fulfil the IPS criteria at the clinical reassessment after 2 years. Six raters evaluated the DAT images blinded to the clinical diagnosis, interpreting the image as being ‘normal’ or ‘pathological’, and assessed the degree of DAT-reduction in the caudate and putamen. The inter-rater agreement was assessed with intra-class correlation and Cronbach’s α. For calculation of sensitivity and specificity, DAT images were defined as correctly classified if categorized as normal or pathological by ≥4/6 raters.

Results: The overall agreement in visual evaluation of the FE-PE2I- and FP-CIT images was high for the IPS patients (α = 0.960 and 0.898, respectively), but lower in healthy controls (FE-PE2I: α = 0.693, FP-CIT: α = 0.657). Visual interpretation gave high sensitivity (both 0.96) but lower specificity (FE-PE2I: 0.86, FP-CIT: 0.63) with an accuracy of 90% for FE-PE2I and 77% for FP-CIT.

Conclusion: Visual evaluation of FE-PE2I PET imaging demonstrates high reliability and diagnostic accuracy for IPS.

Place, publisher, year, edition, pages
Wolters Kluwer, 2023
Keywords
[18F]FE-PE2I PET/computed tomography, diagnostic accuracy, early disease, Parkinson’s disease, PET
National Category
Radiology, Nuclear Medicine and Medical Imaging
Research subject
Radiology; Neurology
Identifiers
urn:nbn:se:umu:diva-206635 (URN)10.1097/mnm.0000000000001679 (DOI)000970601600009 ()36862448 (PubMedID)2-s2.0-85152168200 (Scopus ID)
Funder
Region VästerbottenUmeå UniversityParkinsonfonden
Available from: 2023-04-13 Created: 2023-04-13 Last updated: 2023-09-05Bibliographically approved
Larsson Strömvall, A. & Jakobson Mo, S. (2022). Neuroimaging in nuclear medicine (1ed.). In: Michael Ljungberg (Ed.), Handbook of nuclear medicine and molecular imaging for physicists: volume III, radiopharmaceuticals and clinical applications (pp. 173-188). New York: CRC Press
Open this publication in new window or tab >>Neuroimaging in nuclear medicine
2022 (English)In: Handbook of nuclear medicine and molecular imaging for physicists: volume III, radiopharmaceuticals and clinical applications / [ed] Michael Ljungberg, New York: CRC Press, 2022, 1, p. 173-188Chapter in book (Other academic)
Abstract [en]

Nuclear medicine neuroimaging methods have evolved from mainly being used for research, to becoming established techniques in clinical neurology. In recent years, new technologies have led to increased image quality, and new radiopharmaceuticals with high clinical impact have been developed. The field is expected to become even more important in the future due to the higher prevalence of neurological disorders and the general ageing of the population. The current chapter begins with a basic medical introduction to brain anatomy and physiology. Different pathological conditions such as neurodegenerative disorders, epilepsy, and brain tumours are outlined. The chapter also includes examples of common imaging applications, such as imaging of cerebral blood flow, imaging of brain metabolism, imaging of neurotransmitter systems, and imaging of other cerebral functions such as amyloid and brain tumour imaging. A part on technology is included, discussing neuroimaging solutions for SPECT, SPECT/CT, PET, PET/CT, and PET/MR. Special considerations for optimization of SPECT and PET acquisition and reconstruction are also discussed. Important methods for evaluation, such as visual interpretation and quantitative techniques are also described, including implications for usage of reference databases.

Place, publisher, year, edition, pages
New York: CRC Press, 2022 Edition: 1
Series
Handbook of Nuclear Medicine and Molecular Imaging for Physicists
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-192767 (URN)10.1201/9780429489501-13 (DOI)9781138593312 (ISBN)9781032059563 (ISBN)9780429489501 (ISBN)
Available from: 2022-02-26 Created: 2022-02-26 Last updated: 2022-06-22Bibliographically approved
Jakobson Mo, S., Axelsson, J., J. Stiernman, L., Larsson, A., af Bjerkén, S., Bäckström, D. C., . . . Riklund, K. (2022). VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT. Nuclear medicine communications, 43(3), 247-255
Open this publication in new window or tab >>VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT
Show others...
2022 (English)In: Nuclear medicine communications, ISSN 0143-3636, E-ISSN 1473-5628, Vol. 43, no 3, p. 247-255Article in journal (Refereed) Published
Abstract [en]

OBJECTIVE: To investigate the potential impact of polymorphism in the 3'-untranslated region (3'UTR) of the SLC6A3 gene (DAT1) on normal variation in dopamine transporter (DAT) imaging with [18F]FE-PE2I PET and [123I]FP-Cit SPECT.

METHODS: Thirty-six individuals (mean age 70.4±5.4 years) with normal [18F]FE-PE2I PET and [123I]FP-Cit SPECT were genotyped for variable number of tandem repeats (VNTR) in the 3′UTR of the DAT1 gene. The DAT-availability in the caudate and putamen as measured with [18F]FE-PE2I PET and [123I]FP-Cit SPECT, as well as in the substantia nigra with [18F]FE-PE2I PET were compared between the participants carrying one or two 9-repeat alleles (i.e. 9R+10R or 9R+9R; 47%) and the participants without a 9R allele (i.e. 10R+10R or 10R+11R; 53%). Nonparametric tests, linear regression analysis and mixed model analysis were used to assess any statistical difference in measured DAT availability between the two allele groups.

RESULTS: The measured DAT-availability in PET- and SPECT-imaging tended to be slightly higher in the 9R-group; however, the difference did not reach statistical significance in either the caudate or the putamen or the substantia nigra. Instead, age did have a significant effect on the DAT level (P < 0.05) notwithstanding the genotype.

CONCLUSION: No significant effect of DAT1-genotype was detectable in imaging with [18F]FE-PE2I PET or [123I]FP-Cit, instead, age accounted for the normal variation in DAT-PET and DAT-SPECT.

Place, publisher, year, edition, pages
Wolters Kluwer, 2022
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-192638 (URN)10.1097/MNM.0000000000001514 (DOI)000753310600001 ()34908018 (PubMedID)2-s2.0-85124443503 (Scopus ID)
Funder
Region VästerbottenParkinsonfonden
Available from: 2022-02-22 Created: 2022-02-22 Last updated: 2023-05-24Bibliographically approved
Wallstén, E., Axelsson, J., Jonsson, J., Thellenberg-Karlsson, C., Nyholm, T. & Larsson, A. (2020). Improved PET/MRI attenuation correction in the pelvic region using a statistical decomposition method on T2-weighted images. EJNMMI Physics, 7(1), Article ID 68.
Open this publication in new window or tab >>Improved PET/MRI attenuation correction in the pelvic region using a statistical decomposition method on T2-weighted images
Show others...
2020 (English)In: EJNMMI Physics, E-ISSN 2197-7364, Vol. 7, no 1, article id 68Article in journal (Refereed) Published
Abstract [en]

Background: Attenuation correction of PET/MRI is a remaining problem for whole-body PET/MRI. The statistical decomposition algorithm (SDA) is a probabilistic atlas-based method that calculates synthetic CTs from T2-weighted MRI scans. In this study, we evaluated the application of SDA for attenuation correction of PET images in the pelvic region.

Materials and method: Twelve patients were retrospectively selected from an ongoing prostate cancer research study. The patients had same-day scans of [11C]acetate PET/MRI and CT. The CT images were non-rigidly registered to the PET/MRI geometry, and PET images were reconstructed with attenuation correction employing CT, SDA-generated CT, and the built-in Dixon sequence-based method of the scanner. The PET images reconstructed using CT-based attenuation correction were used as ground truth.

Results: The mean whole-image PET uptake error was reduced from - 5.4% for Dixon-PET to - 0.9% for SDA-PET. The prostate standardized uptake value (SUV) quantification error was significantly reduced from - 5.6% for Dixon-PET to - 2.3% for SDA-PET.

Conclusion: Attenuation correction with SDA improves quantification of PET/MR images in the pelvic region compared to the Dixon-based method.

Place, publisher, year, edition, pages
Springer, 2020
Keywords
PET-MRI, PET, Attenuation correction, Pelvis, Prostate cancer
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-178388 (URN)10.1186/s40658-020-00336-5 (DOI)000595884500002 ()33226495 (PubMedID)2-s2.0-85096433525 (Scopus ID)
Available from: 2021-01-11 Created: 2021-01-11 Last updated: 2023-03-24Bibliographically approved
Wallstén, E., Axelsson, J., Jonsson, J., Thellenberg-Karlsson, C., Nyholm, T. & Larsson, A. (2019). PET/MRI attenuation correction in the pelvic region with a statistical decomposition method. Paper presented at 32nd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, SPAIN, OCT 12-16, 2019. European Journal of Nuclear Medicine and Molecular Imaging, 46(SUPPL 1), S289-S290
Open this publication in new window or tab >>PET/MRI attenuation correction in the pelvic region with a statistical decomposition method
Show others...
2019 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 46, no SUPPL 1, p. S289-S290Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Aim/Introduction: Quantification in PET/MRI is of importance, and its accuracy is currently limited by the MR based attenuation correction estimate. A common method for attenuation correction of the pelvic region is based on a 2-echo Dixon MRI sequence for segmentation of fat and water and does not account for bone. In this work, we evaluate a new method for attenuation correction using an algorithm based on statistical decomposition of a T2 weighted MRI scan.

Materials and Methods: Substitute CT images (sCTs) were calculated from T2 weighted MRI scans with a statistical decomposition algorithm, originally developed for MRI-based radiotherapy dose-planning [1]. These sCTs benefits from having bone density information included, in addition to fat and water information. Prostate cancer patients from the PARAPLY study [2] were retrospectivelyselected, scanned with PET/MRI 11C-Acatate and CT the same day. The stand-alone CT images were transformed to the same geometry as the PET and MR images, using a non-rigid registration. CT images, generated sCT images, and the Dixonbased attenuation maps (MRAC), all in the same geometry, were together with the PET raw data used to reconstruct attenuation-corrected PET images using the PETrecon toolbox [GE Healthcare]. The two MR-based attenuation corrections were compared to the CT-based attenuation correction with root mean squared error (RMSE). Lesion analysis will also be reported. PET/MRI images were acquired on a Signa PET/MRI (GE Healthcare), and the CT images on a Brilliance Big Bore (Phillips Healthcare). The study will include 12 patients and a subset of 6 patients has been analyzed so far and is presented here.

Results: Soft tissue in-between pelvic bone structures were overestimated with 13% in MRAC-PET, and the error was reduced to 5% with sCT attenuation corrected PET (sCT-PET). For the whole patient volume, an average underestimation of 6% was found in the MRAC-PET, compared to 1% for sCTPET. RMSE within the body was reduced with a factor 2.5 with sCT-PET (RMSE=3.6%), compared to MRAC-PET (RMSE=8.8%).

Conclusion: Applying sCT from statistical decomposition as a base for calculation of attenuation maps reduces quantification errors in PET-images of the pelvic region compared to the common Dixon based method.

Place, publisher, year, edition, pages
Springer, 2019
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-165323 (URN)000492444402146 ()
Conference
32nd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, SPAIN, OCT 12-16, 2019
Available from: 2019-12-03 Created: 2019-12-03 Last updated: 2021-04-16Bibliographically approved
Leffler, K., Axelsson, J., Larsson, A., Häggström, I. & Yu, J. (2019). Sharper Positron Emission Tomography: Intelligent Data Sampling to Promote Accelerated Medical Imaging. In: : . Paper presented at Winter Conference in Statistics 2019 - Machine Learning, March 10-14, 2019, Hemavan, Sweden.
Open this publication in new window or tab >>Sharper Positron Emission Tomography: Intelligent Data Sampling to Promote Accelerated Medical Imaging
Show others...
2019 (English)Conference paper, Poster (with or without abstract) (Other academic)
National Category
Probability Theory and Statistics Medical Image Processing
Research subject
Mathematical Statistics
Identifiers
urn:nbn:se:umu:diva-157665 (URN)
Conference
Winter Conference in Statistics 2019 - Machine Learning, March 10-14, 2019, Hemavan, Sweden
Projects
Statistical modelling and intelligent data sampling in MRI and PET measurements for cancer therapy assessment
Funder
Swedish Research Council, 340-2013-534
Available from: 2019-03-28 Created: 2019-03-28 Last updated: 2024-02-06Bibliographically approved
Jakobson Mo, S., Axelsson, J., Jonasson, L., Larsson, A., Ögren, M. J., Ögren, M., . . . Riklund, K. (2018). Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT – a clinical comparison. EJNMMI Research, 8, Article ID 100.
Open this publication in new window or tab >>Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT – a clinical comparison
Show others...
2018 (English)In: EJNMMI Research, E-ISSN 2191-219X, Vol. 8, article id 100Article in journal (Refereed) Published
Abstract [en]

Background: Dopamine transporter (DAT) imaging may be of diagnostic value in patients with clinically suspected parkinsonian disease. The purpose of this study was to compare the diagnostic performance of DAT imaging with positron emission computed tomography (PET), using the recently developed, highly DAT-selective radiopharmaceutical [18F]FE-PE2I (FE-PE2I), to the commercially available and frequently used method with [123I]FP-CIT (FP-CIT) single-photon emission computed tomography (SPECT) in early-stage idiopathic parkinsonian syndrome (PS).

Methods: Twenty-two patients with a clinical de novo diagnosis of PS and 28 healthy controls (HC) participating in an on-going clinical trial of FE-PE2I were analyzed in this study. Within the trial protocol, participants are clinically reassessed 2 years after inclusion. A commercially available software was used for automatic calculation of FP-CIT-specific uptake ratio (SUR). MRI-based volumes of interest combined with threshold PET segmentation were used for FE-PE2I binding potential relative to non-displaceable binding (BPND) quantification and specific uptake value ratios (SUVR).

Results: PET with FE-PE2I revealed significant differences between patients with a clinical de novo diagnosis of PS and healthy controls in striatal DAT availability (p < 0.001), with excellent accuracy of predicting dopaminergic deficit in early-stage PS. The effect sizes were calculated for FE-PE2I BPND (Glass’s Δ = 2.95), FE-PE2I SUVR (Glass’s Δ = 2.57), and FP-CIT SUR (Glass’s Δ = 2.29). The intraclass correlation (ICC) between FE-PE2I BPND FP-CIT SUR was high in the caudate (ICC = 0.923), putamen (ICC = 0.922), and striatum (ICC = 0.946), p < 0.001. Five of the 22 patients displayed preserved striatal DAT availability in the striatum with both methods. At follow-up, a non-PS clinical diagnosis was confirmed in three of these, while one was clinically diagnosed with corticobasal syndrome. In these patients, FE-PE2I binding was also normal in the substantia nigra (SN), while significantly reduced in the remaining patients. FE-PE2I measurement of the mean DAT availability in the putamen was strongly correlated with BPND in the SN (R = 0.816, p < 0.001). Olfaction and mean putamen DAT availability was correlated using both FE-PE2I BPND and FP-CIT SUR (R ≥ 0.616, p < 0.001).

Conclusion: DAT imaging with FE-PE2I PET yields excellent basic diagnostic differentiation in early-stage PS, at least as good as FP-CIT SPECT.

Place, publisher, year, edition, pages
Springer, 2018
Keywords
Parkinson's disease, PET, SPECT, Dopamine transporter (DAT), [F-18]FE-PE2I
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-154944 (URN)10.1186/s13550-018-0450-0 (DOI)000450488800002 ()30443684 (PubMedID)2-s2.0-85056664892 (Scopus ID)
Available from: 2019-01-07 Created: 2019-01-07 Last updated: 2023-03-24Bibliographically approved
Lizana, H., Johansson, L., Axelsson, J., Larsson, A., Ögren, M., Linder, J., . . . Jakobson Mo, S. (2018). Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects. Journal of Nuclear Medicine, 59(8), 1275-1280
Open this publication in new window or tab >>Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
Show others...
2018 (English)In: Journal of Nuclear Medicine, ISSN 0161-5505, E-ISSN 1535-5667, Vol. 59, no 8, p. 1275-1280Article in journal (Refereed) Published
Abstract [en]

F-18-(E)-N-(3-iodoprop-2-enyl)-2 beta-carbofluoroethoxy-3 beta-(4'-methylphenyl) nortropane (F-18-FE-PE2I) was recently developed and has shown adequate affinity and high selectivity for the dopamine transporter (DAT). Previous studies have shown promising results for F-18-FE-PE2I as a suitable radioligand for DAT imaging. In this study, we investigated the whole-body biodistribution and dosimetry of F-18-FE-PE2I in healthy volunteers to support its utility as a suitable PET imaging agent for the DAT. Methods: Five healthy volunteers were given a mean activity of 2.5 MBq/kg, and 3 PET scans, head to thigh, were performed immediately after injection followed by 4 whole-body PET/CT scans between 0.5 and 6 h after injection. Blood samples were drawn in connection with the whole-body scans, and all urine was collected until 6 h after injection. Volumes of interest were delineated around 17 organs on all images, and the areas under the time-activity curves were calculated to obtain the total number of decays in the organs. The absorbed doses to organs and the effective dose were calculated using the software IDAC. Results: The highest activity concentration was observed in the liver (0.9%-1.2% injected activity/100 g) up to 30 min after injection. At later time points, the highest concentration was seen in the gallbladder (1.1%-0.1% injected activity/100 g). The activity excreted with urine ranged between 23% and 34%, with a mean of 28%. The urinary bladder received the highest absorbed dose (119 mu Gy/MBq), followed by the liver (46 mu Gy/MBq). The effective dose was 23 mu Sv/MBq (range, 19-28 mu Sv/MBq), resulting in an effective dose of 4.6 mSv for an administered activity of 200 MBq. Conclusion: The effective dose is within the same order of magnitude as other commonly used PET imaging agents as well as DAT agents. The reasonable effective dose, together with the previously reported favorable characteristics for DAT imaging and quantification, indicates that F-18-FE-PE2I is a suitable radioligand for DAT imaging.

Keywords
F-18-FE-PE2I, dosimetry, biodistribution, DAT, effective dose
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-150823 (URN)10.2967/jnumed.117.197186 (DOI)000440582000020 ()29348315 (PubMedID)2-s2.0-85051260875 (Scopus ID)
Available from: 2018-08-21 Created: 2018-08-21 Last updated: 2023-03-23Bibliographically approved
Wallstén, E., Axelsson, J., Karlsson, M., Riklund, K. & Larsson, A. (2017). A Study of Dynamic PET Frame-Binning on the Reference Logan Binding Potential. IEEE Transactions on Radiation and Plasma Medical Sciences, 1(2), 128-135
Open this publication in new window or tab >>A Study of Dynamic PET Frame-Binning on the Reference Logan Binding Potential
Show others...
2017 (English)In: IEEE Transactions on Radiation and Plasma Medical Sciences, ISSN 2469-7311, Vol. 1, no 2, p. 128-135Article in journal (Refereed) Published
Abstract [en]

Objective: The reference Logan plot is a tool for determining the non-displaceable binding potential for dynamic PET exams using tracers with reversible bindings. Dynamic frame protocols affect noise in PET images and short frames can lead to quantitative uncertainties and noise-induced reconstruction bias. The aim of this study was to analyze the effect of frame binning on 11C-Raclopride striatal binding potential from reference Logan analysis. Methods: 12 healthy volunteers were scanned in list mode using 11C-raclopride, and the image data were reconstructed into 9 different frame binning schemes whereof 3 clinical schemes. Reconstruction was performed with 3 different algorithms, one based on filtered back projection (FBP) and two based on ordered subset expectation maximization (OSEM); one including resolution recovery. Logan plots were used for calculating the non-displaceable binding potential. Variation in binding potential was evaluated using Students t-tests. Results: It was found that frame lengths of up to 60 s gave significantly different results compared to the reference clinical protocol for OSEM, both with and without resolution recovery (maximum deviation: 10.3 % for the 15 s protocol). For FBP, frame lengths of up to 30 s gave significantly different results with a maximum deviation of 2.8 %. The higher sampling dependence of OSEM compared to FBP is likely due to noise-dependent bias in the OSEM algorithm, most apparent at high noise levels. Conclusions: Bias related to OSEM reconstruction of high-noise data is an important factor for dynamic PET protocols. Time frames of 120 s or more generate the most stable values for the striatum binding potential with the reference Logan plot for 11C-Raclopride brain PET.

Place, publisher, year, edition, pages
IEEE, 2017
Keywords
¹¹C-Raclopride, binding potential, dynamic frame protocol, frame binning, Logan analysis, positron emission tomography, time sampling
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
urn:nbn:se:umu:diva-146397 (URN)10.1109/TNS.2016.2639560 (DOI)000456142100003 ()2-s2.0-85113947023 (Scopus ID)
Available from: 2018-04-09 Created: 2018-04-09 Last updated: 2023-03-23Bibliographically approved
Organisations

Search in DiVA

Show all publications